Evidence map›Paper›PMID 26830678›Full record

Trial reportBMC public health2016

No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project.

Stephen Okoboi, Paul John Ekwaru, James D Campbell, Aggrey Egessa, Racheal King, Celestin Bakanda, Emmy Muramuzi, Frank Kaharuza, Samuel Malamba, David M Moore

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephen OkoboiThe AIDS Support Organization-TASO, Headquarters, Mulago Hospital Complex, P.O BOX 10443, Kampala, Uganda. stephenokoboi@yahoo.co.uk.
Paul John EkwaruUniversity of Alberta, Edmonton, Canada. pekwaru@gmail.com.
James D CampbellUniversity of Maryland School of Medicine, Baltimore, MD, USA. jcampbell@medicine.umaryland.edu.
Aggrey EgessaThe AIDS Support Organization-TASO, Headquarters, Mulago Hospital Complex, P.O BOX 10443, Kampala, Uganda. egessaa@tasouganda.org.
Racheal KingUniversity of California, San Francisco, USA. rach@vtx.ch.
Celestin BakandaThe AIDS Support Organization-TASO, Headquarters, Mulago Hospital Complex, P.O BOX 10443, Kampala, Uganda. bakandac@tasouganda.org.
Emmy MuramuziMakerere University School of Public Health, Kampala, Uganda. 6emuba@gmail.com.
Frank KaharuzaMakerere University School of Public Health, Kampala, Uganda. fkaharuz@gmail.com.
Samuel MalambaMakerere University School of Public Health, Kampala, Uganda. malambas@gmail.com.
David M MooreBC Centre for Excellence in HIV/AIDS, Vancouver, Canada. dmoore@cfenet.ubc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda.

methodsBeginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2009. We used Cox Proportional Hazard models to determine if study arm was independently associated with the development of opportunistic infections (OIs) or death.

resultsWe randomized 1211 participants to the three original study arms and 331 surviving participants in the clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. At enrolment the median age was 38 years and the median CD4 cell count was 134 cells/μL. Over a median of 5.2 years of follow-up, 37 deaths and 35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. We did not observe an association between monitoring arm and new OIs or death (AHR =1.19 for CD4-only vs. CD4-VL; 95 % CI 0.82-1.73).

conclusionWe found no differences in clinical outcomes associated with the addition of quarterly VL monitoring to quarterly CD4 cell count monitoring.

Indexed as

Acquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansMaleMiddle AgedUgandaViral LoadAnti-Retroviral Agents

Identifiers

PMID26830678
PMCPMC4736157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.